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Objective: We sought to assess the effect of anticoagulation control on long-term
survival after valve replacement with the Medtronic Hall valve (Medtronic, Inc,
Minneapolis, Minn).
Methods: Prospective follow-up data, including 82,297 international normalized
ratios, were collected for 1476 patients undergoing single valve replacement with
the Medtronic Hall valve between 1979 and 1994, with follow-up to the end of
1998. After excluding 204 patients who either died within 30 days or had fewer than
10 international normalized ratios recorded beyond 30 days, there were 10,203
patient years of follow-up for analysis. Anticoagulation variability was measured as
the percentage of international normalized ratios outside a target range of 2.0 to 4.0
for each patient.
Results: Linearized rates for late death rose progressively with increasing deciles of
anticoagulation variability for both aortic and mitral valve replacement (2.7% and
3.3% per year, respectively, in deciles 1 and 2 up to 9.5% and 14.6% per year,
respectively, in deciles 6-10; P  .001). Survival at 15 years after aortic valve
replacement was 59% for low anticoagulation variability (deciles 1 and 2), 55% for
intermediate anticoagulation variability (decile 3), and 28% for high anticoagulation
variability (deciles 4-10); survivals at 15 years after mitral valve replacement were
56%, 42%, and 24%, respectively (P  .001 between low-intermediate anticoagu-
lation variability and high anticoagulation variability for both aortic and mitral valve
replacement). On multivariate analysis, significant predictors of reduced survival
were anticoagulation variability per 20% increase (hazard ratio, 1.8), diabetes
(hazard ratio, 1.6), decade of age (hazard ratio, 1.6), concomitant coronary artery
bypass grafting (hazard ratio, 1.5), male sex (hazard ratio, 1.4), hypertension (hazard
ratio, 1.4), New York Heart Association class III or IV (hazard ratio, 1.3), and
non-sinus rhythm (hazard ratio, 1.2). Patients with low anticoagulation variability
who were in sinus rhythm and did not have diabetes, coronary bypass grafting, or
hypertension had survivals equal to those of the age- and sex-matched general
population at 15 years. The incidence of valve-related deaths was significantly
higher with high anticoagulation variability compared with the incidence with
low-intermediate anticoagulation variability for both aortic (1.4% vs 0.5% per year,
P  .001) and mitral valve replacement (1.5% vs 0.5% per year, P  .001). By
means of univariate analysis, high anticoagulation variability was significantly
associated with New York Heart Association class III or IV at 5 years postopera-
tively (P  .001) and with age of greater than 60 years at the time of the operation
(P  .002).
Conclusions: High anticoagulation variability is the most important independent
predictor of reduced survival after valve replacement with a mechanical valve.
Better anticoagulation control should improve survival.
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Much of the debate about prostheticvalve choice between mechanicalvalves and bioprostheses revolvesaround anticoagulation and its per-ceived disadvantages.1-3 Althoughoral anticoagulation with coumarin
derivatives has been used therapeutically for 60 years,4 and
for patients with prosthetic heart valves in particular for 40
years, it is only in the last 15 years that anticoagulation has
been placed on a safer and more scientific basis. Progress
toward safer anticoagulation began with the introduction of
standardization of anticoagulation measurement with the
international normalized ratio (INR) in the mid-1980s.5
Oral anticoagulation has always been monitored with the
prothrombin time test, in which a thromboplastin reagent
containing tissue factor is added to the patient’s blood, and
the time taken for a clot to form is compared with that in
normal blood. Thromboplastin reagents are biologic prod-
ucts, typically made from rabbit brain, that vary in their
content of tissue factor from one commercial product to
another. Although different thromboplastin reagents yield
very similar results with normal blood, they may produce
widely differing prothrombin times with anticoagulated
blood. Before the introduction of the INR, the intensity of
anticoagulation was expressed in simple unstandardized
terms either as the prothrombin time or as a prothrombin
ratio in comparison with normal blood. In some European
countries the anticoagulation effect was expressed as a
percentage of normal prothrombin activity remaining (eg,
Thrombotest and Hepato-Quick).
Because of the uncertainty about the true intensity of
anticoagulation, it was clear that some patients were being
anticoagulated at unnecessarily high intensities, particularly
in North America, and thus exposed to a greater risk of
bleeding.6 The introduction of the INR system depended on
calibration of thromboplastin reagents. Each commercial
reagent was accorded an international sensitivity index,
allowing correction of the raw prothrombin ratio to the INR
by using a simple nomogram.5 Although the INR system
was adopted widely in Europe from the mid-1980s onward,
there was initial reluctance to use the new system in North
America, and it did not become widely used in the United
States until the late 1990s.7
The ability to express anticoagulation intensity in stand-
ardized terms allowed better international communication
on this subject and led to progress in defining the optimum
INR range for many conditions and for patients with pros-
thetic heart valves.8 Although not fully worked out for all
types of mechanical valves and all thrombotic risk factors
because of a lack of data, there is now widespread accept-
ance of the principle that the target INR range should be
both prosthesis specific and patient specific.9 In general
there has been a lowering of recommended INRs for low-
thrombogenicity prostheses in recent years, with an associ-
ated reduction in the risk of serious bleeding.10
With standardization of measurement and established
target ranges for some individual types of prostheses, the
only remaining challenge is to improve anticoagulation
control. Some progress has been made in this area with the
demonstration, in several studies, that patient self-manage-
ment with home prothrombin measurement devices results
in a greater percentage of time within the target INR
range.11,12 Two studies have also shown a reduction in both
thromboembolic and bleeding events with patient self-man-
agement.13,14 These studies and others that have shown the
effect of good conventional anticoagulation control in pre-
venting adverse events emphasize the importance of this
aspect of anticoagulation management.15
Although the prevention of thromboembolism and seri-
ous bleeding are essential goals in themselves, the effect of
anticoagulation control on long-term survival in patients
with prosthetic heart valves has not previously been ad-
dressed. We therefore used our 20-year experience with the
Medtronic Hall valve (Medtronic, Inc, Minneapolis, Minn)
to investigate this aspect. We have previously used this
database to define the optimum INR for the Medtronic Hall
valve,16 to demonstrate the importance of stroke risk factors
in determining susceptibility to thromboembolic events af-
ter valve replacement with this prosthesis,17,18 and to doc-
ument the good long-term performance of the Medtronic
Hall valve.19 In patients with single valve replacement,
11,174 patient-years of follow-up and 82,297 individual
INR observations were available for analysis.
Methods
The INR system was introduced in the United Kingdom in the
mid-1980s. Before this, anticoagulation data in this study were col-
lected as the British corrected ratio, which numerically gave values
almost identical to the INR in the therapeutic range. Hence British
corrected ratio and INR data were amalgamated for the purpose of
this analysis, and all data are described in terms of the INR.
The follow-up methods and the anticoagulation protocols used
in our 20-year Medtronic Hall valve study have already been
described.19 Between 1979 and the mid-1980s, all patients were
given a target INR of 2.0 to 3.0. After general recommendations
from European and British hematologists in the mid-1980s that all
patients with prosthetic heart valves (irrespective of type) should
be given a target INR range of 3.0 to 4.5, this higher range was
implemented by most of the anticoagulant clinics that our patients
attended. In practice, the new higher recommendations were intro-
duced cautiously, and although most patients were managed in the
range of 3.0 to 4.0, there was considerable variability in achieved
INRs among the 27 different anticoagulation clinics that the pa-
tients attended, with median INR values varying from 2.2 to 3.9.20
Interim analysis of the effect of the new recommendations on
patients in the Medtronic Hall valve study, in terms of the inci-
dence of thromboembolism and bleeding, led to the definition of
ideal target ranges for patients with this prosthesis,16 and from
1990 onward, patients with aortic valve replacement (AVR) were
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advised to maintain their INR between 2.0 and 3.0. Patients with
mitral valve replacement (MVR) and all patients in atrial fibrilla-
tion were prescribed a range of 3.0 to 4.0. INRs were measured at
4- to 6-week intervals but more frequently if very low or very high
INRs were recorded (1.7 or 5.0). None of the patients in this
study managed their own anticoagulation.
Thus, throughout the study, all patients were managed within
the INR range of 2.0 to 4.0. For the purposes of this analysis,
variability of anticoagulation control (ACV) for each patient was
expressed as the percentage of INR values outside the 2.0 to 4.0
range. ACV data, which ranged from 0% to 100%, were grouped
into deciles and then divided into 3 approximately equal-sized
groups defined as low (0%-19.9% ACV), intermediate (20%-
29.9% ACV), and high (30%) ACV. Only INR values, events,
and deaths after the first 30 days were analyzed because the
purpose of the investigation was to assess the effect of long-term
anticoagulation control. Patients were excluded from the analysis
if they had fewer than 10 documented INR values. The average
number of INR values per patient was 64 (range, 10-331).
The survival of individual patients was examined in relation to
ACV and in relation to the patient risk factors already identified as
predicting reduced survival: diabetes, hypertension, concomitant
coronary artery bypass grafting, and non-sinus rhythm.19 Mortality
statistics for England and Wales from 1993 to 1995 (Series DH1,
number 28, Office for National Statistics, London, United King-
dom) were used for survival comparisons with the age- and sex-
matched general population.
All analyses were performed with the SPLUS software pack-
age, version 2000 (Insightful, Inc, Seattle, Wash). Linearized rates
(LRs) for death by decile of ACV were graphically displayed by
circles proportional in size to the number of follow-up years and
color coded according to low (light gray), intermediate (white),
and high (dark gray) ACV by using the criteria defined above.
Patient survival curves were constructed with the actuarial method
of Kaplan and Meier.21 Survivals in ACV and risk factor groups
were compared by using the log-rank method. The Cox propor-
tional hazard model was used to assess the relationship between
ACV, risk factors, thromboembolism, and major bleeding events
after valve replacement and late survival.22 Thromboembolism and
major bleeding events were treated as time-dependent covariates in
the Cox regression analysis. LRs were compared by using the
likelihood ratio test.23 Associations between ACV and New York
Heart Association (NYHA) class at 5 years postoperatively and
age were tested by using the 2 test.
Results
Patient characteristics and clinical variables for single aortic
and mitral procedures (n  1532) are summarized in Table
1. INR data were collected on 1476 (96%) patients. Of
these, 204 patients were excluded because they had 30 or
fewer days of follow-up (early deaths) or less than 10 INR
values. Of the remaining 1272 patients (10,203 total patient-
years; mean, 8.0 years; SD, 4.2 years; maximum, 18 years),
625 had AVRs (4684 total patient-years; mean, 7.5 years;
SD, 3.9 years; maximum, 18 years), and 647 had MVRs
(5519 total patient-years; mean, 8.5 years, SD, 4.5 years;
maximum, 18 years). Late mortality was 3.7% per year for
AVR and 4.9% per year for MVR.
Of all the INR values collected, 75.5% were within the
target range. Of the 24.5% of INR values outside the range,
12.0% were below 2.0, and 12.5% were above 4.0. ACV
ranged from 0% to 100%, with an average of 27% (SD,
13%) and a distribution that was slightly skewed to the right
(Figure 1).
LRs for death rose with increasing deciles of ACV. For
AVR, LRs ranged from 2.7% per year in deciles 1 and 2
(0%-19.9% ACV) to 7.3% per year in decile 5 (40%-49.9%
ACV) and 9.5% per year in deciles 6 to 10 (50%-100%
ACV, Figure 2). LRs for MVR were higher than those for
AVR, ranging from 3.3% per year in deciles 1 and 2 to
10.3% per year in decile 5 and 14.6% per year in deciles 6
to 10 (Figure 3). For both AVR and MVR, LRs for death in
the low (light gray circles) and intermediate (white circles)
ACV groups were similar but were significantly lower than
in the high ACV group (P  .001).
Survival at 5 years after AVR was 95% in the low ACV
group and 93% in the intermediate ACV group; these results
TABLE 1. Clinical variables by valve position
Aortic Mitral
No. of replacements 625 647
Male (%) 69 27
Age (years)
Mean  SD 60 11 57 10
Range 20-89 13-79
NYHA (%)
1-2 61 43
3-4 39 57
Previous symptoms (%)
Angina pectoris 44 16
Orthopnea 38 66
Myocardial infarction 8 8
Heart failure 29 47
Atrial fibrillation/flutter 10 69
Thromboembolism 6 17
Concomitant disease (%)
Hypertension 21 12
Diabetes mellitus 5 6
Emergency operation (%) 9 5
Previous valve operation (%)
Valve repair/valvotomy 2 28
Valve replacement 5 8
*Valve pathology (%)
Rheumatic 9 73
Endocarditis 5 2
Congenital 52 1
Ischemic 0 4
Degenerative 29 7
Calcific (%) 82 46
Operative diagnosis (%)
Stenosis 59 53
Regurgitation 21 26
Mixed lesion 20 21
*The sum exceeds 100% because some valves have more than one
pathology.
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were not significantly different from those of the UK pop-
ulation. In the high ACV group the survival was signifi-
cantly lower (77%, P  .001 compared with the survival of
the low ACV group). Survival at 15 years was similar for
the low (59%) and intermediate (55%) ACV groups but
significantly reduced in the high ACV group (28%, P 
.001; Figure 4). Results for MVR showed a similar pattern,
but survivals were lower than those for AVR; survival at 5
years was 92%, 90%, and 67% for the low, intermediate,
and high ACV groups, respectively, and survival at 15 years
was 56%, 42%, and 24%, respectively (Figure 5).
Survivals for patients with no risk factors and low or
intermediate ACV were not significantly different from
those of the UK population. With increasing numbers of risk
factors, survivals declined. At 15 years, survival was 45%,
21%, and 13% for groups with 1, 2, and 3 or more risk
factors, respectively (Figure 6).
The incidence of valve-related deaths (including stroke,
thrombosis, major bleeding, and prosthetic valve endocar-
ditis) was significantly higher in the high ACV group com-
pared with that in the low-intermediate ACV group both for
AVR (LRs 1.4% vs 0.5% per year, P  .001) and MVR
Figure 1. The distribution of ACV data in 1272 patients.
Figure 2. LRs for late death (>30 days) after AVR by decile of ACV.
Decile 1 is 0% to 9.9% ACV, decile 2 is 10% to 19.9% ACV, and so
on up to decile 10 (90%-100% ACV). Deciles 1 and 2 have been
combined to give one circle, which represents low variability.
Deciles 6 to 10 have been combined to achieve a minimum of 200
patient-years. The area of each circle is proportional to the
number of patient-years of follow-up in that decile. The circles
are color coded according to low (0%-19.9% ACV; light gray),
intermediate (20%-29.9% ACV; white), and high (>30% ACV; dark
gray) variability.
Figure 3. LRs for late death after MVR by decile of ACV. For
details, see legend to Figure 2.
Figure 4. Late survival (>30 days) by ACV for AVR. ACV is grouped
according to low (0%-19.9% ACV), intermediate (20%-29.9% ACV),
and high (>30% ACV) variability. The numbers above the axis
represent the number of patients at risk at 0, 5, and 10 years,
respectively, within each ACV group.
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(1.5% vs 0.5% per year, P  .001). For AVR, there was a
significantly higher incidence of strokes in the high ACV
group compared with that in the low-intermediate ACV
group (0.7% vs 0.1% per year, P .001) and a trend toward
a higher incidence of major bleeding and prosthetic valve
endocarditis. For MVR, the linearized rate of prosthetic
valve endocarditis was significantly higher in the high ACV
group (0.6% vs 0.07% per year, P  .001), and there was a
trend toward a higher incidence of stroke, thrombosis, and
major bleeding in this group (Table 2).
By means of univariate Cox analysis, significant predic-
tors of reduced survival were traditional risk factors and
ACV (P  .001), major bleeding events (P  .007), throm-
boembolism (P  .038), and both thromboembolism and
major bleeding events (P .001). By means of multivariate
analysis, significant predictors were ACV per 20% increase
(hazard ratio [HR], 1.8), diabetes (HR, 1.6), decade of age
(HR, 1.6), concomitant coronary artery bypass grafting
(HR, 1.5), male sex (HR, 1.4), hypertension (HR, 1.4),
thromboembolism and major bleeding events (HR, 1.3),
valve regurgitation (HR, 1.3), NYHA class III or IV (HR,
1.3), non-sinus rhythm (HR, 1.2), and small valve size (HR,
1.1; Table 3). Valve position was not a significant factor in
the model.
By means of univariate analysis, high ACV was signif-
icantly associated with higher NYHA class (III and IV) at 5
years postoperatively and with older age. In the low-inter-
mediate ACV group, 6% were in NYHA class III or IV, and
44% were above the age of 60 years compared with 12%
and 58% in the high ACV group, respectively (P .001 for
NYHA and .002 for age).
Discussion
Although the importance of good-quality anticoagulation
control in reducing the risk of thromboembolism and bleed-
ing is generally acknowledged, the current analysis demon-
strates for the first time the major effect of anticoagulation
control on long-term survival. High variability in INR was
the strongest independent predictor of reduced survival, and
there was a 32% difference in survival at 15 years between
patients with low and high ACV. When other risk factors for
reduced survival were taken into account and survival was
related to numbers of risk factors (including high ACV),
there was a 55% difference in survival at 15 years between
patients with no risk factors and those with 3 or more risk
factors. The survival of patients with no risk factors was no
different from that of the age- and sex-matched general
population.
LRs of valve-related death were significantly higher in
patients with high ACV for both AVR and MVR. Not only
were there more deaths from stroke and major bleeding
events in patients with high ACV, as expected, but among
patients undergoing MVR, there was a 9-fold increase in
prosthetic endocarditis, which was highly significant (P 
.001). There are 3 possible explanations for this interesting
and unexpected finding. First, periods of low INR could
result in subclinical deposition of thrombus on the sewing
ring of the prosthesis, providing a culture medium for any
circulating bacteria. Second, patients who are poorly com-
pliant with anticoagulation may be poorly compliant with
endocarditis prophylaxis and dental hygiene also. Third,
patients whose high ACV is due to frequent prescription of
antibiotics that interact with warfarin would clearly be ex-
posed to more frequent infections. The most common cause
of frequent antibiotic prescriptions is lower respiratory tract
infection, and this would be in keeping with a strong asso-
ciation with prosthetic endocarditis in the mitral position.
Thus, it is possible that the relationship between high ACV
and prosthetic endocarditis is either causative or simply an
Figure 5. Late survival by ACV for MVR. For details, see legend to
Figure 4.
Figure 6. Late survival by number of risk factors (both valve
positions). Risk factors are diabetes, hypertension, concomitant
coronary artery bypass grafting, non–sinus rhythm, and high ACV
(>30% ACV).
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association caused by other factors. Further investigation of
this unexpected relationship is required.
Overall, the findings in this study have implications for
the interpretation of prosthetic valve data and for the anti-
coagulation management of all patients with prosthetic heart
valves.
Prosthetic Heart Valve Performance
Traditionally, prosthetic heart valves, whether mechanical
or biologic, have been compared in terms of patient survival
and the incidence of adverse events.1 This study confirms
the findings of others that patient factors exert a major
influence on survival24-28 but also shows that these factors
are additive in their effect and that ACV (never measured in
most studies) is the most important independent factor.
Determining the effect of the prosthesis itself on survival
in any study is fraught with difficulties because even com-
parison with age- and sex-matched general population data
from the same country has limitations. On the one hand,
there may be selection bias if only patients with good
general performance status and no significant comorbidities
are chosen for surgical treatment. On the other hand, in
reality patients undergoing heart valve replacement tend to
have a higher prevalence of risk factors that adversely affect
survival (atrial fibrillation, left ventricular hypertrophy, and
coronary artery disease) than the general population.
In this study patients who had no significant risk factors
for reduced survival and low ACV had a 15-year survival
identical to that of the general population. Although open to
the criticism that the general population would also have
some of these risk factors that were not excluded, it is likely
that the prevalence of these risk factors in the general
population would be much less and that today many would
be treated effectively (eg, atrial fibrillation, hypertension,
and coronary artery disease), thus reducing their effect on
survival data. Although admittedly imperfect, comparison
of survival with that of the general population, having
excluded significant nonprosthetic risk factors, provides a
better means of assessing prosthetic performance than un-
stratified survival data and may allow more meaningful
comparison of one prosthesis with another.
The skeptics and proponents of bioprosthetic valves may
say how much better it would be to avoid anticoagulation
altogether because poorly managed anticoagulation control
has such an adverse effect on survival. However, structural
valve deterioration is a major determinant of reduced sur-
vival in patients with bioprostheses,2 and it could be argued
TABLE 2. Valve-related deaths by ACV grouped
Aortic Mitral
Low/medium ACV n
(%/yr)
High ACV
n (%/yr)
Low/medium ACV n
(%/yr)
High ACV
n (%/yr)
Patients 420 205 436 211
Patient-years 3454 1230 4106 1413
Stroke 5 (0.1) 8 (0.7)*** 8 (0.2) 5 (0.4)
Thrombosis 0 (0) 0 (0) 1 (0.02) 1 (0.07)
Major bleeding 8 (0.2) 6 (0.5) 9 (0.2) 7 (0.5)
PVE 3 (0.09) 3 (0.2) 3 (0.07) 8 (0.6)***
Total 16 (0.5) 17 (1.4)*** 21 (0.5) 21 (1.5)***
ACV, Anticoagulant variability; PVE, prosthetic valve endocarditis.
***P  .001.
TABLE 3. Cox regression risk factors for late survival over a 20-year period
Coefficient P value HR
ACV (per 20% increase) 0.595 .001 1.813
Diabetes 0.497 .007 1.644
Decade of age 0.489 .001 1.630
Concomitant CABG 0.413 .002 1.511
Male sex 0.371 .001 1.448
Hypertension 0.361 .010 1.434
TE/BE 0.281 .021 1.324
Valve regurgitation 0.252 .016 1.287
NYHA class III or IV 0.245 .020 1.277
Non–sinus rhythm 0.216 .087 1.241
Small valve size 0.073 .001 1.075
ACV, Anticoagulant variability; TE, thromboembolism; BE, major bleed; HR, hazard ratio.
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that efforts to improve anticoagulation control can only
result in an even greater overall survival advantage with
mechanical valves than has already been demonstrated by
the only randomized trial of mechanical valves versus bio-
prostheses to report 15-year results.2 Despite the use of
first-generation tilting disc valves and a high incidence of
bleeding events, probably associated with unstandardized
anticoagulation measurement, this randomized trial was still
able to demonstrate a survival advantage at 15 years in
patients with mechanical aortic valves. A randomized trial
carried out now, using the least thrombogenic mechanical
valves and high-quality anticoagulation management,
would be likely to show an even more marked survival
advantage.
Improving Anticoagulation Control
Because anticoagulation control has such a dramatic influ-
ence on survival after valve replacement, it is essential that
further efforts are made to improve control and to identify
the causes of high ACV. The finding in this study that high
variability in INR is significantly associated with higher
NYHA class may be due to the fact that most patients with
impaired performance status are taking multiple medica-
tions, raising the risk of warfarin interaction and INR insta-
bility. Functionally compromised patients may also be less
compliant with medication and less compliant in attending
anticoagulation clinics. High INR variability was also asso-
ciated with older age. Older patients tend to have more
comorbidities and consequently take a greater number of
medications. They may also be more forgetful in taking
their warfarin regularly. Studies of bleeding risk in patients
taking anticoagulants have demonstrated the importance of
multiple comorbidities in increasing the risk,29 and it is
likely that this increased risk is mediated through high INR
variability.
Other possible causes of high ACV in this study will be
the subject of further analysis. We have already documented
considerable variation in achieved INR among groups of
patients attending 27 different anticoagulation clinics (me-
dian INR ranged from 2.2-3.9).20 Anticoagulation intensity
that is maintained close to either end of the INR target range
is more likely to go outside the range, and this may be an
important factor. Test frequency has also been shown to
have an effect on INR variability, with more frequent testing
increasing the time in target range.5,12 Although long-acting
coumarin derivatives, such as phenprocoumon (used in
some European countries), are associated with more stable
INR control, one study of 6814 patients showed that the
incidence of bleeding complications was higher, possibly
because a high INR will take longer to return to the target
range.30
A study of compliance with anticoagulation carried out
in the United States showed that younger, male patients who
had not experienced any thromboembolic events were more
likely to forego INR testing. On univariate analysis, other
factors associated with poor compliance were nonwhite
ethnic origin (odds ratio [OR], 6.4), working full time (OR,
5.6), and lack of health insurance (OR, 5.6). On multiple
logistic regression, the latter 2 factors were not independ-
ently predictive, but nonwhite race remained marginally
significant (P  .06). Compliance was not affected by
income, marital status, or education.31
Another recent American study comparing “usual med-
ical care” with that in an anticoagulation clinic run by a
clinical pharmacist showed that the latter treatment strategy
improved anticoagulation control, reduced bleeding and
thromboembolic event rates, and saved over $160,000 per
100 patients annually in reduced hospitalizations and emer-
gency department visits.32 Several studies have also shown
the value of patient self-management in conjunction with
home prothrombin testing in improving the percentage of
time spent within the prescribed INR range.11-14,33 It is
likely that the use of self-management will increase rapidly
in those countries in which the portable measurement de-
vices are now readily obtainable. In the future, it can be
anticipated that most patients with prosthetic heart valves
will manage their own anticoagulation with the same facil-
ity that persons with diabetes manage their insulin require-
ments and that self-management will become the norm,
allowing patients to lead fuller, safer lives and to travel
without restriction. Compliance is also likely to be im-
proved if patients do not need to take time off work to attend
an anticoagulation clinic or pay for their INR to be meas-
ured.
Good anticoagulation control also involves patient edu-
cation, and most studies of self-management have empha-
sized this aspect. A recent randomized, multicenter trial
evaluated a structured teaching and self-management pro-
gram for anticoagulated patients in comparison with con-
ventional anticoagulation management by family physicians
and found not only more INR values in the target range but
also higher patient satisfaction scores on a quality-of-life
questionnaire.33 Patients need a basic understanding of an-
ticoagulation and, if they choose, training in the use of a
home prothrombin measurement device and warfarin dos-
age adjustment. They also need dietary advice about the
antagonistic effects of foods containing large quantities of
vitamin K34 and education about the effect on the INR of
drug interactions with warfarin.35 Patients unable to under-
take self-management may choose to delegate this respon-
sibility to a close relative or may prefer to attend an anti-
coagulation clinic regularly. However, in this case choice of
anticoagulation clinic is important. All anticoagulation clin-
ics should audit their performance regularly according to
agreed upon criteria,5 and these audit data should be made
available to referring clinicians and patients. Despite high
INR variability in some patients in this study, overall anti-
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coagulation management was reasonably good, with 75% of
INR values within the target range. Other authors have
reported as few as 50% or less of INR values in the target
range,11,33,36 and the need for considerable improvement in
the quality of anticoagulation management by individual
physicians and by anticoagulation clinics has been empha-
sized.37
Whatever method is chosen, the potential for better an-
ticoagulation control to improve survival in patients with
prosthetic heart valves seems enormous and may outweigh
the influence of other factors. Traditionally, surgeons seek
technical solutions to improve long-term survival for their
patients, but in the case of valve-replacement surgery, en-
suring good long-term anticoagulation control is likely to
have the greatest effect on survival. It is no longer sufficient
simply to begin a patient on warfarin and hope for the best.
Cardiac surgeons and physicians caring for patients with
prosthetic valves have a major responsibility to ensure that
their patients receive the best possible anticoagulation man-
agement.
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Discussion
Dr D. Craig Miller (Stanford, Calif). It is a pleasure to be
asked to discuss an article by Eric Butchart. He is a widely
respected cardiac surgeon who is also known as a meticulous,
rigorous, and honest clinical investigator. You are also the father,
Eric, of the concept of site-specific and valve type–specific anti-
coagulation. I think our patients have benefited from this advance.
Is it correct that the anticoagulation target values in your study
complied with the global UK guidelines as set by the hematolo-
gists 2 to 4? You have previously shown conclusively for aortic
mechanical valves (and particularly for the Medtronic-Hall valve)
that an INR in the 2 to 3 range is fine, as is 3 to 4 for the mitral
valves. What was your benchmark for adequacy of anticoagulation
control in this study: the UK standards or your own personal
standards?
Dr Butchart. You are quite right to say that during this very
long period of the study, 20 years, we used slightly different INR
ranges, but to look at ACV, we broadened the range to an INR of
2 to 4. At one stage, we were managing all patients at an INR
between 2 and 3, and then we followed national recommendations
and went up to an INR of 3 to 4 or 4.5.
Dr Miller. Okay. I have another question. If I saw one of your
slides correctly, it indicated that there were 60 INRs per patient.
Now, some of these persons have been followed for many, many
years. Did that number actually mean 60 INR values per patient
per year?
Dr Butchart. No, all together. That was an average of 64 per
patient. The range was up to 300 per patient.
Dr Miller. Thank you. Was all this postoperative anticoagula-
tion management performed in your UK anticoagulation clinics,
which are run by the hematologists?
Dr Butchart. There is quite a lot of variation actually. Most are
run by hematologists. Some are run by general physicians, and
some are run by general practitioners.
Dr Miller. Which leads me to my next question. I was struck
by the fact that there appears to be little or no home or patient-
controlled anticoagulation monitoring yet in Britain.
Dr Butchart. That’s right. It is because the National Health
Service can not afford it.
Dr Miller. Well, let’s talk about that. Is it being done today, at
least in your center in the UK?
Dr Butchart. No. We have not started it yet. We are consid-
ering starting a study looking at that, but the problem and the
reason it has not been introduced in the UK is simply one of cost.
I did not have time to show the data, but there are at least 5 studies
in the literature now that have shown significant benefit from use
of home prothrombin measurements and patients managing their
own anticoagulation.
Dr Miller. We know from the Scandinavian and German
experiences that patient benefit and safety are provided by home
anticoagulation control, but are there not also favorable cost im-
plications?
Dr Butchart. Yes, I think there will be positive cost implica-
tions, with savings in hospital admissions and in patients making
visits to the doctor to have their INRs measured.
Dr Miller. I am sorry to say that self-anticoagulation at home
probably still is not widely used in the United States, although it is
Food and Drug Administration approved. This is because many
insurance companies seem to balk at paying for the machines and
the disposable supplies. Therefore, we also may be a third-world
country when it comes to this aspect of health care.
Looking at the HRs, the ones that had the biggest effect on
survival were variability of anticoagulation and age, which I be-
lieve was 1.2 per decade. That seemingly low risk adds up if you
talk about many decades. The other patient-related risk factors had
only very small effects on survival. What I learned from you—and
the data do stand on their own merits and the conclusions are well
substantiated—is that how well you control the patient’s postop-
erative anticoagulation is probably a whole heck of a lot more
important than what type of mechanical valve you put in.
Dr Butchart. Yes. Almost certainly, that’s right. Probably the
single most important thing that we can do for our patients is to
ensure that they have good-quality anticoagulation control.
Dr Miller. In the future, do you have any new drugs coming on
the scene in Europe, for example new recombinant warfarin-type
compounds or direct antithrombin inhibitors? Is there ever going to
be an oral anticoagulant that is safer than warfarin? We forget that
the warfarin and dicumerol family of drugs has now been around
for over 45 years.
Dr Butchart. There may well be eventually, but I think we are
a long way off from that.
Dr Miller. Still?
Dr Butchart. Yes.
Dr Miller. Very nicely presented, Eric. I think it is fair to say
that most in the audience believe you. Thank you for being here
with us.
Dr Butchart. Thank you very much, indeed.
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